All In MedTech

FDA Clearance Tracker · K232761

ProNephro AKI™ (NGAL)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Dec 7, 2023 (this decision)Source: openFDAMethods & limitations

510(k)Breakthrough

Decided

Dec 7, 2023

Substantially Equivalent

Time to decision

90 days

Received Sep 8, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K232761
Device name
ProNephro AKI™ (NGAL)
Applicant location
Needham, MA
Received
Sep 8, 2023
Decided
Dec 7, 2023
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 862.1220

Every decision under product code PIG

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PIG. The earliest in FDA's data is DEN130031, decided Sep 5, 2014.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Bioporto Diagnostic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.